MS21570
(Synonyms: 5-(苄基硫代)-N-甲基-1,3,4-噻二唑-2-胺) 目录号 : GC30894
MS21570是GPR171的选择性拮抗剂，其IC50值为220nM.
Cas No.:65373-29-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Mice[1]Male C57bl/6J or AgRP-IRES-Cre mice are 8-12 weeks old at the beginning of the experiment. Mice are habituated to the testing room 1 h prior to each experiment. Behaviors are videotaped and analyzed. Mice are injected with MS21570 (MS0021570_1: 5 mg/kg, i.p.) 15 min prior to elevated plus maze, open field, forced swim and contextual fear conditioning. For microinjection studies, MS21570 is injected 10 min prior testing and immediately following the contextual fear conditioning. Singly housed AgRP-IRES-Cre mice with cre-inducible DREADD in the arcuate nucleus receive MS21570 (3.5 mg/kg, i.p.) or vehicle (6% DMSO in saline) 15 min prior to CNO (1 mg/kg, i.p.) or saline injection. Food intake is measured at 1, 2, 4, and 8 hours post-injection[1]. |
References: [1]. Bobeck EN, et al. The BigLEN-GPR171 Peptide Receptor System Within the Basolateral Amygdala Regulates Anxiety-Like Behavior and Contextual Fear Conditioning. Neuropsychopharmacology. 2017 Dec;42(13):2527-2536. | |
MS21570 is a selective GPR171 antagonist, with an IC50 of 220 nM.
MS21570 significantly attenuates this CNO-mediated increase in food intake. Interestingly, MS21570 causes a significant increase in center time compared to vehicle suggesting an effect on the anxiety-like behavior. Intra-BLA administration of MS21570 leads to an increase in open arm time on the elevated plus maze although there is no effect on locomotor activity during this test. Interestingly, when administered before and immediately following fear conditioning, MS21570 significantly attenuates freezing measured 24 hours later. Behavioral differences between systemic and intra-BLA administration of MS21570 could be due to the pharmacokinetic and pharmacodynamic properties of the drug. Further studies are needed to characterize the GPR171 antagonist[1].
[1]. Bobeck EN, et al. The BigLEN-GPR171 Peptide Receptor System Within the Basolateral Amygdala Regulates Anxiety-Like Behavior and Contextual Fear Conditioning. Neuropsychopharmacology. 2017 Dec;42(13):2527-2536.
| Cas No. | 65373-29-7 | SDF | |
| 别名 | 5-(苄基硫代)-N-甲基-1,3,4-噻二唑-2-胺 | ||
| Canonical SMILES | CNC1=NN=C(SCC2=CC=CC=C2)S1 | ||
| 分子式 | C10H11N3S2 | 分子量 | 237.34 |
| 溶解度 | DMSO : 125 mg/mL (526.67 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.2134 mL | 21.0668 mL | 42.1336 mL |
| 5 mM | 0.8427 mL | 4.2134 mL | 8.4267 mL |
| 10 mM | 0.4213 mL | 2.1067 mL | 4.2134 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。